1. Linfoma de Hodkin en Chile: Experiencia de 15 años del Programa Nacional de Cáncer del Adulto
- Author
-
M Elena Cabrera C, Hernán García L, Vivian Lois V, Alvaro León R, Karina Peña N, Alberto Rossle S, Berta Cerda A, Hernán Rojas R, Pedro Meneses C, Carlos Merino M, Augusto Aspillaga M, Cecilia Vittini de R, Jacqueline Oliva L, Cecilia Hales D, and Janet Rosas H
- Subjects
medicine.medical_specialty ,Prognostic factor ,Hodgkin disease ,Radiotherapy ,business.industry ,Mixed cellularity ,Treatment outcome ,Advanced stage ,Follow up studies ,Dacarbazina ,General Medicine ,Gastroenterology ,chemotherapy, adjunvant ,Multicenter study ,ABVD ,Internal medicine ,medicine ,Antineoplastic protocols ,business ,medicine.drug - Abstract
Background: Hodgkin lymphoma is a highly curable disease. Aim: To evaluate the clinical characteristics and the treatment results of Hodgkin lymphoma patients of the National Cancer Program in Chile. Patients and methods: Prospective assessment of 682 patients treated in 18 adult cancer centers. Progression free survival (PFS) and overall survival (OS) were calculated. Median follow up was 127, 95, 87, 72 and 50 months for C-MOPP, radiotherapy (RT), C-MOPP/ABV, NOVP and ABVD, respectively. Results: Median age was 37 years (15-84). Nodular sclerosis and mixed cellularity were equally expressed. Advanced stages (III & IV) were present at diagnosis in 61% of cases. Age over 40 was an adverse prognostic factor (p
- Published
- 2007
- Full Text
- View/download PDF